Zynex (NASDAQ:ZYXI) Releases Q2 2024 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its second quarter 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.080- for the period, compared to the consensus estimate of 0.070. The company issued revenue guidance of $52.0 million-, compared to the consensus revenue estimate of $53.1 million. Zynex also updated its FY 2024 guidance to 0.500- EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Royal Bank of Canada boosted their target price on shares of Zynex from $13.00 to $15.00 and gave the stock an outperform rating in a research report on Friday, March 1st. HC Wainwright boosted their target price on shares of Zynex from $20.00 to $21.00 and gave the stock a buy rating in a research report on Friday, March 1st.

Zynex Stock Performance

ZYXI traded down $0.48 during trading on Tuesday, reaching $10.97. 156,977 shares of the company’s stock were exchanged, compared to its average volume of 233,517. Zynex has a fifty-two week low of $6.88 and a fifty-two week high of $14.75. The company has a quick ratio of 4.03, a current ratio of 4.74 and a debt-to-equity ratio of 1.26. The business has a 50 day moving average price of $12.38 and a 200 day moving average price of $10.81. The company has a market capitalization of $352.90 million, a P/E ratio of 40.63 and a beta of 0.48.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings results on Thursday, February 29th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.13). Zynex had a return on equity of 16.82% and a net margin of 5.28%. The business had revenue of $47.28 million for the quarter, compared to analyst estimates of $54.53 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The firm’s quarterly revenue was down 3.1% on a year-over-year basis. As a group, analysts predict that Zynex will post 0.49 earnings per share for the current fiscal year.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.